Trial · NCT06132035
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage of occurrence of Adverse Events (AE) | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Primary | The number of Adverse Events (AE) that occurs | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Primary | Change in IOP with study drug compared to placebo | Screening, Day 0, Day 28, Day 56 & Day 84 | Mean change in intraocular pressure (IOP) with study drug compared to placebo from baseline to end of study |
| Primary | Change in intraocular inflammation with study drug compared to placebo | Screening, Day 0, Day 28, Day 56 & Day 84 | Mean change in intraocular inflammation with study drug compared to placebo from baseline to end of study |
| Primary | Incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo | Day 0, Day 28, Day 56 & Day 84 | Mean change in incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo with study drug compared to placebo from baseline to end of study |
| Secondary | Change in best corrected visual acuity (BCVA) of study drug compared to Eylea® and placebo as measured by ≥15 Early ETDRS letter score at the end of 84 days | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Change in CNV area on fluorescence angiography with study drug compared to Eylea® and placebo on day 28, day 56 and day 84 | Day 28, Day 56 & Day 84 | |
| Secondary | Mean decrease in central retinal thickness on SD-OCT with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Mean decrease in total macular volume on optical coherence tomography with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in BCVA with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Number of patients with change in BCVA with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in intraocular pressure (IOP) with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Number of patients with change in intraocular pressure (IOP) with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in intraocular inflammation with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Number of patients with change in intraocular inflammation with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in central retinal thickness with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Number of patients with change in central retinal thickness with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in total macular volume with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Number of patients with change in total macular volume with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Change from Baseline in Choroidal Neovascularization (CNV) area as measured by Fluorescein Angiography (FA) over the study duration | Screening, Day 0, Day 28, Day 56 & Day 84 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06132035/registered